The HLA-A2 restricted T cell epitope HCV core35-44 stabilizes HLA-E expression and inhibits cytolysis mediated by natural killer cells

American Journal of Pathology

Volumn 166, Issue 2, 2005, Pages 443-453

  Nattermann, Jacob ^a   Nischalke, Hans Dieter ^a   Hofmeister, Valeska ^b   Ahlenstiel, Golo ^a   Zimmermann, Henning ^a   Leifeld, Ludger ^a   Weiss, Elisabeth H ^b   Sauerbruch, Tilman ^a   Spengler, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD94 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; HLA E ANTIGEN; IMMUNOGLOBULIN RECEPTOR;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD SAMPLING; CELL ISOLATION; CHROMIUM 51 RELEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; FLOW CYTOMETRY; GENETIC TRANSFECTION; HEPATITIS C VIRUS; HUMAN; IMMUNOPEROXIDASE STAINING; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 13244257273     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62267-5     Document Type: Article

References (46)

1. Botarelli P, Brunetto MR, Minutello MA, Calvo P, Unutmaz D, Weiner AJ, Choo QL, Shuster JR, Kuo G, Bonino F, Houghton M, Abrignani S: T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993, 104:580-587
2. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N, Purcell RH: Lack of protective immunity against reinfection with hepatitis C virus. Science 1992, 258:135-140
3. Spengler U, Lechmann M, Irrgang B, Dumoulin FL, Sauerbruch T: Immune responses in hepatitis C virus infection. J Hepatol 1996, 24:20-25
4. Corado J, Toro F, Rivera H, Bianco NE, Deibis L, De Sanctis JB: Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection. Clin Exp Immunol 1997, 109:451-457
5. Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, Mosca M, Filliponi F, Brunetto RM, Bonino F, Abrignani S, Valiante NM: Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 2002, 195:35-41
6. Duesberg U, Schneiders AM, Flieger D, Inchauspe G, Sauerbruch T, Spengler U: Natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) is not impaired in patients suffering from chronic hepatitis C. J Hepatol 2001, 35:650-657
7. Trinchieri G: Biology of natural killer cells. Adv Immunol 1989, 47:187-376
8. Ulbrecht M, Martinozzi S, Grzeschik M, Hengel H, Ellwart JW, Pla M, Weiss EH: Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis. J Immunol 2000, 164:5019-5022
9. Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S, Cerundolo V, Borysiewicz LK, McMichael AJ, Wilkinson GW: Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000, 287:1031
10. Xu XN, Screaton GR, McMichael AJ: Virus infections: escape, resistance, and counterattack. Immunity 2001, 15:867-870
11. Braud VM, McMichael AJ: Regulation of NK cell functions through interaction of the CD94/NKG2 receptors with the nonclassical class I molecule HLA-E. Curr Top Microbiol Immunol 1999, 244:85-95
12. Wei XH, Orr HT: Differential expression of HLA-E, HLA-F, and HLA-G transcripts in human tissue. Hum Immunol 1990, 29:131-142
13. Ulbrecht M, Honka T, Person S, Johnson JP, Weiss EH: The HLA-E gene encodes two differentially regulated transcripts and a cell surface protein. J Immunol 1992, 149:2945-2953
14. Stevens J, Joly E, Trowsdale J, Butcher GW: Peptide binding characteristics of the non-classical class Ib MHC molecule HLA-E assessed by a recombinant random peptide approach. BMC Immunol 2001, 2:5
15. Ulbrecht M, Modrow S, Srivastava R, Peterson PA, Weiss EH: Interaction of HLA-E with peptides and the peptide transporter in vitro: implications for its function in antigen presentation. J Immunol 1998, 160:4375-4385
16. Pietra G, Romagnani C, Falco M, Vitale M, Castriconi R, Pende D, Millo E, Anfossi S, Biassoni R, Moretta L, Mingari MC: The analysis of the natural killer-like activity of human cytolytic T lymphocytes revealed HLA-E as a novel target for TCR alpha/beta-mediated recognition. Eur J Immunol 2001, 31:3687-3693
17. Schweitzer S, Schneiders AM, Langhans B, Kraas W, Jung G, Vidalin O, Inchauspe G, Sauerbruch T, Spengler U: Flow cytometric analysis of peptide binding to major histocampatibility complex class I for hepatitis C virus core T-cell epitopes. Cytometry 2000, 41:271-278
18. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE: HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol 1998, 160:4951-4960
19. Li J, Goldstein I, Glickman-Nir E, Jiang H, Chess L: Induction of TCR Vbeta-specific CD8+ CTLs by TCR Vbeta-derived peptides bound to HLA-E. J Immunol 2001, 167:3800-3808
20. Michaelsson J, Teixeira de Matos C, Achour A, Lanier LL, Karre K, Soderstrom K: A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J Exp Med 2002, 196:1403-1414
21. Llano M, Lee N, Navarro F, Garcia P, Albar JP, Geraghty DE, Lopez-Botet M: HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur J Immunol 1998, 28:2854-2863
22. Vales-Gomez M, Reyburn HT, Erskine RA, Lopez-Botet M, Strominger JL: Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E. EMBO J 1999, 18:4250-4260
23. Vales-Gomez M, Reyburn H, Strominger J: Interaction between the human NK receptors and their ligands. Crit Rev Immunol 2000, 20:223-244
24. Kawarabayashi N, Seki S, Hatsuse K, Ohkawa T, Koike Y, Aihara T, Habu Y, Nakagawa R, Ami K, Hiraide H, Mochizuki H: Decrease of CD56(+)T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology 2000, 32:962-969
25. Battegay M, Fikes J, Di Bisceglie AM, Wentworth PA, Sette A, Celis E, Ching WM, Grakoui A, Rice CM, Kurokohchi K, Berzofsky JK, Hoofnagle JH, Feinstone SM, Akatsuka T: Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995, 69:2462-2470
26. Braud VM, Aldemir H, Breart B, Ferlin WG: Expression of CD94-NKG2A inhibitory receptor is restricted to a subset of CD8+ T cells. Trends Immunol 2003, 24:162-164
27. Jabri B, Selby JM, Negulescu H, Lee L, Roberts AI, Beavis A, Lopez-Botet M, Ebert EC, Winchester RJ: TCR specificity dictates CD94/NKG2A expression by human CTL. Immunity 2002, 17:487-499
28. Moser JM, Gibbs J, Jensen PE, Lukacher AE: CD94-NKG2A receptors regulate antiviral CD8(+) T cell responses. Nat Immunol 2002, 3:189-195
29. Nattermann J, Nischalke H, Feldmann G, Sauerbruch T, Spengler U: Enhanced expression of CD94/NKG2A on CD8+T lymphocytes from HCV-positive patients. Hepatology 2003, 38(4):466A-466A 633 Suppl. 1
30. Martinozzi S, Pacasova R, Boulouis HJ, Ulbrecht M, Weiss EH, Sigaux F, Pla M: Cutting edge: requirement of class I signal sequence-derived peptides for HLA-E recognition by a mouse cytotoxic T cell clone. J Immunol 1999, 162:5662-5665
31. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL, McMichael AJ: HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391:795-799
32. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG: Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998, 187:813-818
33. Miller JD, Weber DA, Ibegbu C, Pohl J, Altman JD, Jensen PE: Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2. J Immunol 2003, 171:1369-1375
34. Paul RG, Roodman ST, Campbell CR, Bodicky CJ, Perrillo RP: HLA class I antigen expression as a measure of response to antiviral therapy of chronic hepatitis B. Hepatology 1991, 13:820-825
35. Chu CM, Shyu WC, Kuo RW, Liaw YF: HLA class I antigen display on hepatocyte membrane in chronic hepatitis B virus infection: its role in the pathogenesis of chronic type B hepatitis. Hepatology 1988, 8:712-717
36. Rouger P, Poupon R, Gane P, Mallissen B, Darnis F, Salmon C: Expression of blood group antigens including HLA markers in human adult liver. Tissue Antigens 1986, 27:78-86
37. Lautenschlager I, Taskinen E, Inkinen K, Lehto VP, Virtanen I, Hayry P: Distribution of the major histocompatibility complex antigens on different cellular components of human liver. Cell Immunol 1984, 85:191-200
38. Onji M, Kikuchi T, Kumon I, Masumoto T, Nadano S, Kajino K, Horiike N, Ohta Y: Intrahepatic lymphocyte subpopulations and HLA class I antigen expression by hepatocytes in chronic hepatitis C. Hepatogastroenterology 1992, 39:340-343
39. Pietra G, Romagnani C, Mazzarino P, Millo E, Moretta L, Mingari MC: Comparative analysis of NK- or NK-CTL-mediated lysis of immature or mature autologous dendritic cells. Eur J Immunol 2003, 33:3427-3432
40. Wong P, Pamer EG: Feedback regulation of pathogen-specific T cell priming. Immunity 2003, 18:499-511
41. Ronchese F, Hermans IF: Killing of dendritic cells: a life cut short or a purposeful death? J Exp Med 2001, 194:F23-F26
42. Del Prete GF, De Carli M, Ricci M, Romagnani S: Helper activity for immunoglobulin synthesis of T helper type 1 (Th1) and Th2 human T cell clones: the help of Th1 clones is limited by their cytolytic capacity. J Exp Med 1991, 174:809-813
43. Cerboni C, Mousavi-Jazi M, Wakiguchi H, Carbone E, Karre K, Soderstrom K: Synergistic effect of IFN-gamma and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity. Eur J Immunol 2001, 31:2926-2935
44. Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, Rabbani H, Moretta A, Soderstrom K, Levitskaya J, Kiessling R: IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 2002, 110:1515-1523
45. Wang EC, McSharry B, Retiere C, Tomasec P, Williams S, Borysiewicz LK, Braud VM, Wilkinson GW: UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proc Natl Acad Sci USA 2002, 99:7570-7575
46. Falk CS, Mach M, Schendel DJ, Weiss EH, Hilgert I, Hahn G: NK cell activity during human cytomegalovirus infection is dominated by US2-11-mediated HLA class I down-regulation. J Immunol 2002, 169:3257-3266